Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jun;10(3):351-364.
doi: 10.1007/s13555-020-00373-z. Epub 2020 Apr 2.

Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available Evidence

Jashin J Wu  1 , Joseph F Merola  2 , Steven R Feldman  3 , Alan Menter  4 , Mark Lebwohl  5
Affiliations
Review

Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available Evidence

Jashin J Wu et al. Dermatol Ther (Heidelb). 2020 Jun.

Erratum in

Abstract

Psoriasis (PsO) is a common, systemic, chronic, inflammatory disease characterized by key clinical symptoms, including itching, pain, and scaling. PsO is associated with a high prevalence of comorbidities, including other autoimmune diseases and malignancies. Furthermore, special populations, such as pregnant, pediatric, and elderly patients, and those with erythrodermic PsO, are challenging to treat and require tightly monitored disease and treatment management. Because certain populations have demographic or clinical characteristics that can affect the presentation of PsO and complicate treatment responses, these patient populations are largely excluded from clinical trials; therefore, most clinical evidence for the treatment of these patients is derived from case reports and series. Secukinumab, a fully human monoclonal interleukin-17A antibody, has been shown in several clinical trials to be effective and safe for the treatment of PsO; however, these studies offer only limited data on the use of secukinumab in patients with chronic illnesses or in special populations. This review explores the use of secukinumab for PsO in special populations, including pregnant women, children, elderly people, patients with erythrodermic PsO, and those with chronic illnesses, including latent tuberculosis, hepatitis B and C, HIV, multiple sclerosis, and malignancies.

Keywords: HIV; Hepatitis; IL-17A inhibitor; Malignancies; Pediatric; Pregnancy; Psoriasis; Secukinumab; Tuberculosis.

PubMed Disclaimer

Conflict of interest statement

Jashin J. Wu is or has been an investigator, consultant, or speaker for AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Dermavant, Dermira, Dr. Reddy’s Laboratories, Eli Lilly, Janssen, LEO Pharma, Novartis, Regeneron, Sanofi Genzyme, Sun Pharmaceutical, UCB, and Valeant Pharmaceuticals North America LLC. Joseph F. Merola is a consultant and/or investigator for Merck Research Laboratories, AbbVie, Dermavant, Eli Lilly, Novartis, Janssen, UCB, Samumed, Celgene, Sanofi, Regeneron, GSK, Almirall, Sun Pharmaceutical, Biogen, Pfizer, Incyte, Aclaris, and LEO Pharma. Steven R. Feldman received research, speaking, and/or consulting support from Galderma, GSK/Stiefel, Almirall, Alvotech, LEO Pharma, Bristol Myers Squibb, Boehringer Ingelheim, Mylan, Celgene, Pfizer, Ortho Dermatology, AbbVie, Samsung, Janssen, Eli Lilly, Menlo, Merck, Novartis, Regeneron, Sanofi, Novan, Qurient, National Biological Corporation, Caremark, Advance Medical, Sun Pharma, Suncare Research, Informa, UpToDate, and the National Psoriasis Foundation; he is founder and majority owner of www.DrScore.com and founder and part owner of Causa Research, a company dedicated to enhancing patients’ adherence to treatment. Alan Menter is an investigator for AbbVie, Allergan, Amgen, ApoPharma, Boehringer Ingelheim, Celgene, Convoy Therapeutics, Genentech, Janssen Biotech, Eli Lilly, LEO Pharma, Merck, Novartis, Pfizer, Symbio/Maruho, and Wyeth; receives research funds from AbbVie, Allergan, Amgen, ApoPharma, Boehringer Ingelheim, Celgene, Convoy Therapeutics, Genentech, Janssen Biotech, LEO Pharma, Merck, Pfizer, Symbio/Maruho, and Syntrix; and is an advisor, consultant, and/or speaker for and received honoraria from AbbVie, Allergan, Amgen, Boehringer Ingelheim, Convoy Therapeutics, Eli Lilly, Genentech, Janssen Biotech, LEO Pharma, Novartis, Pfizer, Syntrix, Wyeth, and XenoPort. Mark Lebwohl is an employee of Mount Sinai and receives research funds from AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Celgene, Eli Lilly, Incyte, Janssen/Johnson & Johnson, Kadmon, LEO Pharma, MedImmune, Novartis, Pfizer, SciDerm, UCB, Ortho Dermatologics, and Vidac; and is a consultant for Allergan, Almirall, Arcutis, Avotres, BirchBioMed, Boehringer Ingelheim, Bristol Myers Squibb, Cara, Castle Biosciences, Dermavant, Encore, Inozyme, LEO Pharma, Meiji, Menlo, Mitsubishi Pharma, NeuroDerm Ltd, Pfizer, Promius/Dr. Reddy, Theravance Biopharma, and Verrica. Steve Feldman and Mark Lebwohl are members of the journal’s Editorial Board. Alan Menter is an Editor-in-Chief of this journal.

References

    1. Myers WA, Gottlieb AB, Mease P. Psoriasis and psoriatic arthritis: clinical features and disease mechanisms. Clin Dermatol. 2006;24(5):438–447. doi: 10.1016/j.clindermatol.2006.07.006. - DOI - PubMed
    1. Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70(3):512–516. doi: 10.1016/j.jaad.2013.11.013. - DOI - PubMed
    1. Lonnberg AS, Zachariae C, Skov L. Targeting of interleukin-17 in the treatment of psoriasis. Clin Cosmet Investig Dermatol. 2014;7:251–259. doi: 10.2147/CCID.S67534. - DOI - PMC - PubMed
    1. Blauvelt A, Prinz JC, Gottlieb AB, et al. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE) Br J Dermatol. 2015;172(2):484–493. doi: 10.1111/bjd.13348. - DOI - PubMed
    1. Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis–results of two phase 3 trials. N Engl J Med. 2014;371(4):326–338. doi: 10.1056/NEJMoa1314258. - DOI - PubMed

LinkOut - more resources